Press News

Press News

2013.08.06 tella Establishes an Alliance with Kitasato Institute (Kitasato University Kitasato Institute Hospital)

tella, Inc. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Yuichiro Yazaki;
hereinafter “the Company”) signed an alliance agreement with the Kitasato Institute (Address: Minato-ku,
Tokyo; Chairman of the Board of Trustees: Kiyotaka Fujii). Under this alliance, we have started
providing technologies and know-how concerning the DC vaccine therapy*1 to Kitasato University
Kitasato Institute Hospital (hereinafter “Kitasato Institute Hospital”). This hospital will start clinical
studies concerning the DC vaccine therapy in the fall of 2013 at its Tumor Center. In conjunction with
these studies, the hospital will perform studies involving advanced medical treatments and the approval
of drugs. This alliance raised the number of contracted medical institutions to 30.
Kitasato Institute Hospital was started as a Tsukushigaoka Youjouen in 1893, established by Dr.
Shibasaburo Kitasato as Japan’s first sanitarium for tuberculosis. The sanitarium became a general
hospital in 1973. The Kitasato Institute was incorporated as an academic corporation in 2008, becoming
Kitasato Institute Hospital of Kitasato University. In 2010, the hospital was certified by the Tokyo
metropolitan government as a cancer treatment hospital*2. This certification recognizes the hospital’s
ability to provide a comprehensive and fully integrated lineup of treatments. This includes the three major
treatments for cancer: surgery, chemical therapy and radiation therapy. Treatments also extend to
preventive measures, palliative care, medical care at home and other activities.
The Tumor Center of Kitasato Institute Hospital is dedicated to the hospital’s mission of providing
“medical care with a heart.” To accomplish this, the center adheres to the basic policy of providing
medical care that reflects the condition and wishes of each patient along with the provision of standard
care. The activated self-lymphocyte injection method using a patient’s own tumor*3, which is one type of
immunotherapy, has been approved as an advanced medical treatment and the Tumor Center uses this
treatment as part of its basic policy.
The Company is committed to making an even greater contribution to the care of cancer patients by
providing its technologies and know-how involving the DC vaccine therapy to even more hospitals and
other partners.
This matter will have only a negligible effect on results of operations in fiscal 2013.

TopPage